International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set. [Review]
No Thumbnail Available
All Authors
Samuel, R.
Knight, SR.
Adams, R.
Das, P.
Dorth, J.
Finch, D.
Guren, MG.
Hawkins, MA.
Moug, S.
Rajdev, L.
LTHT Author
Samuel, Robert
Sebag-Montefiore, David
Sebag-Montefiore, David
LTHT Department
Leeds Cancer Centre
Oncology
Oncology
Non Medic
Publication Date
2024
Item Type
Journal Article
Review
Review
Language
Subject
Subject Headings
Abstract
Variation in outcomes definitions and reporting limit the utility of clinical trial results. The Core Outcome Research Measures in Anal Cancer (CORMAC) project developed a core outcome set (COS) for chemoradiotherapy trials for anal squamous cell carcinoma (ASCC) through an international healthcare professional and patient consensus process. The CORMAC-COS comprises 19 outcomes across 4 domains (disease activity, survival, toxicity, life impact). In CORMAC-2 we have established standardised definitions for the 11 disease activity and survival outcomes in the CORMAC COS. Definitions were agreed through a 3 step process, initially identifying existing definitions through systematic review (registered with PROSPERO, CRD42016036540), using these to populate a two-round Delphi questionnaire completed by 51 experts from 13 countries, and finally ratification through an online consensus meeting. Standardising the definitions for these core outcomes facilitates real world utilisation of the CORMAC-COS, thereby increasing the quality of data available for clinical decision-making and ultimately enhancing patient care.
Journal
EClinicalMedicine